Abstract

Background and AimsImaging tools for predicting pancreatic atrophy after steroid therapy in autoimmune pancreatitis (AIP) have not been established. As delayed equilibrium‐phase contrast enhancement in computed tomography (CE‐CT) may reflect interstitial fibrosis, we evaluated the ability of equilibrium‐phase CT imaging for predicting pancreatic atrophy.MethodsForty‐six steroid‐treated AIP patients who underwent contrast‐enhanced CT at our university hospital were included in this retrospective study. CT attenuation (Hounsfield units [HU]) values in noncontrast images (NC) and equilibrium‐phase images (EP) and the differences in HU values between NC and EP images (SUB) were measured. Pancreatic volume was measured in CE‐CT before (Volpre) and after (Volpost) steroid therapy. The volume reduction rate was calculated. The relationships of CT values with pancreatic atrophy, Volpost, volume reduction rate, and diabetes exacerbation were investigated.ResultsCT values in the EP and SUB images before steroid therapy were associated with pancreatic atrophy after steroid therapy (atrophy vs nonatrophy 114.5 ± 12.8 vs 99.5 ± 11.1, P = 0.0002; 70.9 ± 14.72 vs 57.2 ± 13.1, P = 0.003, respectively), but CT values in NC images were not (P = 0.42). CT values in EP and SUB images before steroid therapy were correlated with Volpost (EP images r = −0.70, P = 0.002; SUB images r = −0.68, P = 0.03) and volume reduction rate after steroid therapy (EP images: r = −0.55, P < 0.0001; SUB images r = −0.45, P = 0.002). Diabetes exacerbation was associated with higher EP and SUB values (P = 0.009 and P = 0.04, respectively).ConclusionEquilibrium‐phase contrast CT imaging may facilitate prediction of pancreatic atrophy after steroid therapy in AIP.

Highlights

  • The pathogenesis of autoimmune pancreatitis (AIP) is assumed to involve autoimmune mechanisms with unknown etiology.[1]Given its immune-related mechanisms, steroid therapy is recommended as a first-line therapy in the International ConsensusDiagnostic Criteria for AIP and the Japanese Clinical Guidelines for AIP.[2]

  • Steroid therapy was effective in all treated patients (n = 46)

  • Six months after commencing steroid therapy, pancreatic atrophy was observed in 14 patients but not in the remaining

Read more

Summary

Introduction

The pathogenesis of autoimmune pancreatitis (AIP) is assumed to involve autoimmune mechanisms with unknown etiology.[1]Given its immune-related mechanisms, steroid therapy is recommended as a first-line therapy in the International ConsensusDiagnostic Criteria for AIP and the Japanese Clinical Guidelines for AIP.[2]. Given its immune-related mechanisms, steroid therapy is recommended as a first-line therapy in the International Consensus. The influence of steroid therapy on diabetes control in AIP remains controversial. Pancreatic atrophy after steroid therapy was closely related to the incidence of new onset of diabetes or exacerbation of diabetes, and most patients required insulin therapy even in the maintenance phase of AIP.[10] the predictors of pancreatic atrophy before steroid therapy remain unknown. Prediction of pancreatic atrophy before steroid therapy will enable identification of patients who should receive early therapeutic intervention for diabetes or nonsteroid therapy, such as immune-modulatory agents. Imaging tools for predicting pancreatic atrophy after steroid therapy in autoimmune pancreatitis (AIP) have not been established. As delayed equilibrium-phase contrast enhancement in computed tomography (CE-CT) may reflect interstitial fibrosis, we evaluated the ability of equilibrium-phase CT imaging for predicting pancreatic atrophy

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call